文献速递术前评估与围术期医学区域麻醉与超声

围术期地塞米松在假体周围关节感染手术中的应用:糖尿病分层倾向评分匹配回顾性队列研究

Perioperative Dexamethasone in Periprosthetic Joint Infection Surgery: Diabetes-Stratified Results From a Propensity Score-Matched Retrospective Cohort Study.
PubMed 文献 · Anesth Analg · 2026-04-27

该回顾性队列研究纳入2015至2023年因假体周围关节感染行翻修全关节置换术的成年患者,按地塞米松暴露进行1:1倾向评分匹配,非糖尿病组30644例、糖尿病组14996例。结果显示地塞米松与两组复合并发症、伤口并发症及感染并发症减少相关,糖尿病组还观察到死亡率显著下降。

要点

  • 地塞米松与糖尿病和非糖尿病患者的复合并发症减少均相关。
  • 地塞米松与伤口并发症和感染并发症减少相关。
  • 仅糖尿病患者观察到死亡率显著下降。

核心结论

  • 地塞米松在因假体周围关节感染行首次翻修全关节置换术的患者中似乎是安全的,无论糖尿病状态如何。
  • 地塞米松与复合并发症、伤口并发症及感染并发症的几率降低相关,且在糖尿病患者中获益可能更大。

研究设计与样本

  • 回顾性队列研究,使用美国全支付方医院数据集,纳入2015至2023年≥18岁因髋或膝关节假体周围感染行翻修全关节置换术的患者。
  • 共识别61527例患者,非糖尿病组30644例和糖尿病组14996例按地塞米松暴露进行1:1倾向评分匹配,匹配良好。

主要发现

  • 非糖尿病组复合并发症调整比值比(aOR)0.934,95%置信区间(CI)0.760-0.978;糖尿病组aOR 0.814,95%CI 0.746-0.889。
  • 非糖尿病组伤口并发症aOR 0.891,95%CI 0.823-0.964;糖尿病组aOR 0.879,95%CI 0.787-0.981。
  • 非糖尿病组感染并发症aOR 0.891,95%CI 0.823-0.964;糖尿病组aOR 0.827,95%CI 0.754-0.908。
  • 仅糖尿病组死亡率显著下降,aOR 0.692,95%CI 0.532-0.901。

临床怎么用

  • 对于因假体周围关节感染行首次翻修全关节置换术的患者,围术期地塞米松可考虑用于减少并发症,无需因糖尿病状态而回避。

局限性

  • 作为回顾性研究,存在残留混杂的可能性,结果应谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dexamethasone is used in primary total joint arthroplasty (TJA) to reduce postoperative nausea and vomiting, and there is emerging evidence that it also ameliorates adverse events more broadly. Despite a lack of supporting data, a vocal minority has continued to question the appropriateness of dexamethasone in cases where the hyperglycemic burden and/or risk of infection are increased. This study sought to assess the benefits and potential harms of dexamethasone in a cohort of patients undergoing revision TJA for periprosthetic joint infection (PJI). We hypothesize that perioperative dexamethasone exposure is associated with fewer postoperative complications, regardless of diabetes status. METHODS: An all-payer, US hospital-based dataset was queried. Patients ≥18 years with a diagnosis of hip or knee PJI between 2015 and 2023 were identified using billing and procedural codes, and verified using hospital charges for antibiotics and spacers. The primary outcome was composite complications. Secondary outcomes (wound and infectious complications, as well as mortality) were evaluated to probe for potential safety signals. RESULTS: In total, 61,527 patients were identified. A total of 30,644 nondiabetic patients and 14,996 diabetic patients were 1:1 matched based on dexamethasone exposure, with good balance. Dexamethasone-treated patients had fewer aggregate complications in both cohorts (nondiabetic: adjusted odds ratio [aOR], 0.934 and 95% confidence interval [CI], 0.760-0.978; diabetic: aOR, 0.814 and 95% CI, 0.746-0.889). Dexamethasone was also associated with fewer wound complications (nondiabetic: aOR, 0.891 and 95% CI, 0.823-0.964; diabetic: aOR, 0.879 and 95% CI, 0.787-0.981) and infectious complications (nondiabetic: aOR, 0.891 and 95% CI, 0.823-0.964; diabetic: aOR, 0.827 and 95% CI, 0.754-0.908). Only diabetic patients saw a statistically significant decrease in mortality (aOR, 0.692 and 95% CI, 0.532-0.901). CONCLUSIONS: As with any retrospective study, findings should be interpreted cautiously due to the possibility of residual confounding. Nevertheless, dexamethasone appears to be safe to use in patients undergoing first-stage revision for TJA for PJA regardless of diabetic status. Further, findings suggest that dexamethasone is associated with lower odds of aggregate complications, and contrary to conventional wisdom, these benefits may be even greater among diabetics.

来源:Anesth Analg,查看原文。版权归原作者所有。

引用

  1. Jones IA, Wier J, Iyer A, et al. Perioperative Dexamethasone in Periprosthetic Joint Infection Surgery: Diabetes-Stratified Results From a Propensity Score-Matched Retrospective Cohort Study. Anesth Analg. 2026. PMID: 42044508. doi:10.1213/ANE.0000000000008049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。